Home » About Us » Medical Advisory Board

Medical Advisory Board

 

Naomi’s Fund has a short and long term vision for funding and the Medical Advisory Board that make the decisions on how funds are awarded.

 

Phase I – Interim Medical Advisory Board

The interim board will focus on proven research projects that need to secure initial seed funding for research studies that will lead toward later phases; e.g. Clinical trials.

Two oncologists from leading cancer and research institutions will advise the executive board of Naomi’s Fund on request for proposal specifics and awarding funds.

 

Dr. John Cunningham

Dr. Cunningham is an internationally-renowned expert in the treatment and research of childhood cancers and blood diseases. He has particular expertise in treating hemoglobinopathies, which are disorders that affect red blood cells, such as sickle cell and thalassemia. He is a recognized leader in the field of pediatric stem cell transplantation, and has developed novel uses for this life-saving treatment.

An active researcher, Dr. Cunningham is studying the biology and therapy of hemoglobinopathies, the development of clinical trials for the treatment of genetic diseases, and transcriptional mechanisms operative during the development of vertebrate organisms. Over his distinguished career, Dr. Cunningham’s research has received support from the National Heart, Lung, and Blood Institute, the American Society of Hematology, and other prominent scientific organizations. He is vice chair of the American Cancer Society Molecular Genetics and Oncogenes Study Section.

Dr. Cunningham is an accomplished author and has published more than 50 scientific articles, as well as several book chapters and invited reviews. He has served on the editorial board of the Journal of Biological Chemistry, and is a reviewer for Blood, Molecular and Cellular Biology, Cancer Research, and Genomics. A popular speaker, Dr. Cunningham has lectured at universities and scientific meetings around the world. Before joining the University of Chicago as Chief of the Section of Pediatric Hematology/Oncology, Dr. Cunningham was a leader in the Division of Experimental Hematology and Bone Marrow Transplantation at St. Jude Children’s Research Hospital in Memphis, Tennessee.

 

Dr. Winston Huh

Winston W. Huh, MD is a recognized expert in the treatment of pediatric soft tissue sarcomas at the Children’s Cancer Hospital of the University of Texas M.D. Anderson Cancer Center.  Dr. Huh also has an active interest in the biology and treatment of bone sarcomas, rare tumors of childhood, and late-effects of therapy.

Dr. Huh has published over 30 peer-reviewed and invited publications and book chapters.  He is currently an Associate Professor of Pediatrics at the University of Texas MD Anderson Cancer Center and is also a member of the Children’s Oncology Group and the Connective Tissue Oncology Society.

 

Phase II – Medical Advisory Board

Naomi’s Fund will assemble a full Medical Advisory Board when reserves reach $100,000. In addition to raising and granting small sums of money through the interim Medical Board, Naomi’s Fund will set aside a percentage of funds raised to build the reserve for the distribution per the suggestions of the eventual full Medical Advisory Board. This money will allow Naomi’s Fund to have greater future impact by committing ongoing support to highly promising research projects.

The make-up of the full Medical Advisory Board will include oncology professionals representing all aspects of pediatric cancer care and research, for a balanced perspective, including:

  • Oncologists
  • Oncology Surgeons
  • Oncology Radiologist
  • Oncology Nurses
  • Oncology/Medical Administrators